

Metabolic Signatures of *Acinetobacter baumannii* and *Klebsiella pneumoniae* Infections in Acute-on-chronic Liver Failure

Info

PUBLISHED DATE

2026-01-01

JOURNAL


Cellular and Molecular Gastroenterology and Hepatology

LINK

<https://doi.org/10.1016/j.jcmgh.2025.101707>

Authors

Camilla Cadoli Sania Arif Wibke Ballhorn
Angela Brieger Maximilian Joseph Brol
Florence Castelli Hans-Peter Erasmus Julia Fischer
Robert Gurke Lisa Hahnefeld Christophe Junot
Nico Kraus Cristina Ortiz Robert Schierwagen
Sara Garcia Torres Frank Erhard Uschner
Volker Müller Jonel Trebicka Christoph Welsch
Volkhard A.J. Kempf



Abstract

Background & Aims

Acute-on-chronic liver failure (ACLF) is a life-threatening syndrome of acute hepatic decompensation (AD) that leads to multiorgan failure and high mortality. Bacterial infections are often implicated in ACLF pathogenesis; however, their underlying molecular mechanisms remain poorly understood. This study employed a combined in vitro-ex vivo metabolomics approach to investigate infection-associated metabolic alterations relevant to ACLF.

Methods

Gut (Caco-2) cells were infected with *Acinetobacter baumannii* and *Klebsiella pneumoniae* strains. Metabolite profiling was conducted on cell culture supernatants, and selected metabolites were tested for hepatotoxicity in vitro using liver (HepG2) cells. Metabolomic analysis of sera from 2 independent patient cohorts (AD and ACLF) was conducted to validate in vitro findings and to assess their clinical relevance.

Results

Distinct metabolic signatures were identified in *Abaumannii* (19 metabolites) and *Kpneumoniae* (15 metabolites)-infected Caco-2 cells. Four key metabolites from each bacterial species were prioritized for further experiments: α -ketoglutarate, indoleacetic acid, p-coumaric acid, uridine (*Abaumannii*), desthiobiotin, N8-acetylspermidine, N-acetylglutamine, and β -pinene (*Kpneumoniae*). Hepatotoxicity was demonstrated in liver (HepG2) cells exposed to Caco-2 infected cell-derived supernatants, infection-associated metabolites, and metabolite mixtures (in all conditions, $P < .0001$). Increased levels of α -ketoglutarate ($P = .0002$), N-acetylglutamine ($P = .0153$), indoleacetic acid ($P < .05$), and N8-acetylspermidine ($P < .01$) have been confirmed in the sera of patients with AD and ACLF.

Conclusions

Our findings suggest that metabolites associated with bacterial infections and hepatotoxic potential are significantly elevated in patients with AD and ACLF. These compounds may contribute to disease-related metabolic disturbances, representing promising candidates as early diagnostic biomarkers and targeted therapeutic strategies for ACLF.